Quick Answer
IDEAYA Biosciences, Inc. reported Net Income Loss of -$113.70 million for the year ending 2025.
- IDEAYA Biosciences, Inc. showed an increase of +58.6% in Net Income Loss from 2024 to 2025.
- This data is from IDEAYA Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$5.74 million | Q2 2018: -$7.00 million | Q3 2018: -$13.05 million | Q4 2018: -$8.56 million | Q1 2019: -$9.57 million | Q2 2019: -$10.66 million | Q3 2019: -$10.97 million | Q4 2019: -$10.78 million | Q1 2020: -$12.04 million | Q2 2020: -$12.39 million | Q3 2020: -$4.93 million | Q1 2021: -$9.02 million | Q2 2021: -$10.95 million | Q3 2021: -$11.58 million | Q1 2022: -$14.01 million | Q2 2022: -$22.06 million | Q3 2022: $1.62 million | Q1 2023: -$23.64 million | Q2 2023: -$27.93 million | Q3 2023: -$27.44 million | Q1 2024: -$39.57 million | Q2 2024: -$52.77 million | Q3 2024: -$51.82 million | Q1 2025: -$72.18 million | Q2 2025: -$77.49 million | Q3 2025: $119.24 million.
- Over the full 9 years of available data (2017 to 2025), IDEAYA Biosciences, Inc.'s Net Income Loss has declined by 858.5%.
- Historical annual values: Fiscal year 2025: -$113.70 million | Fiscal year 2024: -$274.48 million | Fiscal year 2023: -$112.96 million | Fiscal year 2022: -$58.66 million | Fiscal year 2021: -$49.76 million | Fiscal year 2020: -$34.50 million | Fiscal year 2019: -$41.98 million | Fiscal year 2018: -$34.35 million | Fiscal year 2017: -$11.86 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: